Biotech in the New Year. Plus: Beyond Biosecure

Picks, perils and predictions for biopharma in 2025 — the latest BioCentury podcast

Can biotech break free of the macro factors that have buffeted the industry of late? On the first BioCentury This Week podcast of 2025, BioCentury’s editors offer their predictions for the New Year and — exploring the themes from Simone Fishburn’s latest Letter from the Editor — ask whether biotech can overcome the financing environment, policy concerns and geopolitical tension that have been hammering the industry to deliver on the meaningful strides companies have been taking to deliver innovations to patients.

Plus, Washington Editor Steve Usdin discusses what U.S. policymakers need to do now in the wake of a year’s worth of wrangling over the Biosecure Act, and Executive Editor Selina Koch breaks down readouts from Neumora Inc. (NASDAQ:NMRA) on its KOR antagonist navacaprant to treat major depressive disorder and  Axsome Therapeutics Inc. (NASDAQ:AXSM) for its AXS-05 to treat agitation in Alzheimer’s patients.